China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026)

China Pharma Holdings (CPHI) has reported Change in Accured Expenses for 17 consecutive years, with $191211.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 5.94% year-over-year to $191211.0; the trailing twelve-month figure through Jun 2026 stood at $541028.0 (down 30.13% YoY), and the FY2025 full-year result was $465753.0, up 8.01% from the prior year.
• Change in Accured Expenses climbed to $191211.0 in Q2 2026 per CPHI's latest filing, from -$14258.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $804339.0 in Q4 2022 and bottomed at -$450887.0 in Q1 2023.
• Historically, Change in Accured Expenses has averaged $112438.3 across 5 years, with a median of $66141.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses sank 579.2% in 2022, then surged 940.44% in 2023.
• Over 5 years, Change in Accured Expenses stood at $804339.0 in 2022, then tumbled by 47.67% to $420886.0 in 2023, then jumped by 73.24% to $729131.0 in 2024, then slumped by 40.64% to $432777.0 in 2025, then plunged by 55.82% to $191211.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $191211.0, -$14258.0, and $432777.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.